Summary We are seeking an enthusiastic and highly motivated Senior Research Associate of Biochemistry and Biophysics to join the Early Discovery team based in Cambridge, MA. You will be working on developing novel Alpha Radioligand Therapy with a focus on developing biochemical and biophysical assays as well as performing compound screening to support ARTBIO's pipeline. You must be highly motivated, detail-oriented, willing to learn new techniques, and be comfortable presenting results to cross-functional teams.
\n ResponsibilitiesParticipate in designing and developing biochemical and biophysical experiments to characterize the binding of small molecules and peptides to targets of interest.Execute biochemical and biophysical assays, including, but not limited to, SPR, ITC, TR-FRET, AlphaLisa.Maintain detailed records, analyze and interpret the data, generate SAR reports.Develop protocols for method transfer.Effectively interact with colleagues in cell biology, medicinal chemistry, translational research, plus other functional groups. Present scientific work at the internal meetings.Stay scientifically current and adopt emerging technologies to drug discovery process. Qualifications & EducationBS or master's degree in biochemistry, biophysics, or related discipline, with at least 2 years of experience in drug discovery in an industry setting is required.Previous experience of using biochemical and biophysical technologies to characterize the binding of small molecules and peptides to targets of interest is required.Experienced in performing biochemistry and biophysics assays, such as SPR, ITC, MST, TR-FRET, AlphaLisa, and etc.Exceptional interpersonal and communication skills, and ability to work seamlessly with multiple drug discovery teams to provide technical support at all stages of the project.Ability to multi-task and collaborate effectively with other scientists and research associates to accomplish goals on tight timelines.Skilled at working in a multi-disciplinary environment, a track record of team working and collaboration.
\nAbout Us ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn and Twitter. As an emerging, global biotech with locations in Boston, Massachusetts, Basel, Switzerland, London, England and Oslo, Norway, we take advantage of diverse scientific depth and insights which makes ARTBIO a unique place to work. We are driven by a desire to do better for cancer patients, lowering the burden of toleration and safety while at the same time raising the bar on clinical efficacy and duration. EEO Statement ARTBIO is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you have a disability or special need that requires accommodation, please let us know.